Retraction Note to: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF [Cancer Immunology, Immunotherapy,57, (2008) 1007-1016, DOI 10.1007/s00262-007-0431-z];Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 1007-1016

  Yamamoto, Nobuto ^a   Suyama, Hirofumi ^b   Nakazato, Hiroaki ^c   Yamamoto, Nobuyuki ^a   Koga, Yoshihiko ^d  

^a Socrates Institute for Therapeutic Immunology   (United States)

^b Nagasaki Immunotherapy Research Group   (Japan)

^c Yokoyama Hospital for Gastroenterological Diseases   (Japan)

^d Nakagawa Hospital   (Japan)

Author keywords

Colorectal cancer; Deglycosylation; Immunosuppression; Immunotherapy; Macrophage activating factor; Macrophages; N acetylgalactosaminidase

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; MACROPHAGE ACTIVATING FACTOR; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CELL SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; LONG TERM CARE; MACROPHAGE; MALE; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION;

EID: 42649110411     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1616-x     Document Type: Erratum

References (48)

1. 1. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 172 248 254 10.1016/0003-2697(76)90527-3 Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 172:248–254
2. 2. S Braun K Pantel 1999 Micrometastatic bone marrows involvement detection and prognostic significance Med Oncol 16 154 165 10523795 10.1007/BF02906127 1:STN:280:DyaK1Mvls1ehsA%3D%3D Braun S, Pantel K (1999) Micrometastatic bone marrows involvement detection and prognostic significance. Med Oncol 16:154–165
3. 3. AM Cohen B Shank MA Friedman 1989 Colorectal cancer VT Devita Jr S Hellman SA Rosenberg Cancer, principle and practice of oncology, 3 J.B. Lippincott Philadelphia 895 964 Cohen AM, Shank B, Friedman MA (1989) Colorectal cancer. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, principle and practice of oncology, 3rd edn. J.B. Lippincott, Philadelphia, pp 895–964
4. 4. JJ DeCosse GJ Tsioulias JS Jacobson 1994 Colorectal cancer: detection, treatment and rehabilitation CA Cancer J Clin 44 27 42 8281470 10.3322/canjclin.44.1.27 1:STN:280:DyaK2c7gvVyhuw%3D%3D DeCosse JJ, Tsioulias GJ, Jacobson JS (1994) Colorectal cancer: detection, treatment and rehabilitation. CA Cancer J Clin 44:27–42
5. 5. DF Gleason 1977 The Veteran,s Administration Cooperative Urological Research Group: histological grading and clinical staging of prostate carcinoma M Tannenbaum Urologic pathology: the prostate Lea and Febiger Philadelphia 171 198 Gleason DF (1977) The Veteran,s Administration Cooperative Urological Research Group: histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea and Febiger, Philadelphia pp 171–198
6. 6. P Gold SQ Freedman 1965 Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques J Exp Med 121 439 462 14270243 10.1084/jem.121.3.439 1:STN:280:DyaF2M%2FnsVOqug%3D%3D 2137957 Gold P, Freedman SQ (1965) Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462
7. 7. S Homma N Yamamoto 1990 Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol Clin Exp Immunol 79 307 313 2178824 10.1111/j.1365-2249.1990.tb05195.x 1:CAS:528:DyaK3cXhslKnsLk%3D 1534768 Homma S, Yamamoto N (1990) Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol 79:307–313
8. 8. S Homma M Yamamoto N Yamamoto 1993 Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine Immunol Cell Biol 71 249 257 8225394 10.1038/icb.1993.29 1:CAS:528:DyaK2cXhs1Wgt7k%3D Homma S, Yamamoto M, Yamamoto N (1993) Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol 71:249–257
9. 9. S Kanda Y Mochizuki Y Miyata H Kanetake N Yamamoto 2002 Vitamin D-binding protein-derived macrophage activating factor, GcMAF, has an antiangiogenic activity both in vivo and in vitro J Natl Cancer Inst 94 1311 1319 12208896 10.1093/jnci/94.17.1311 1:CAS:528:DC%2BD38XntVGqtbY%3D Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N (2002) Vitamin D-binding protein-derived macrophage activating factor, GcMAF, has an antiangiogenic activity both in vivo and in vitro. J Natl Cancer Inst 94:1311–1319
10. 10. O Kisker S Onizuka CM Becker M Fannon E Flynn R D’Amato B Zetter J Folkman R Ray N Swamy S Pirie-Shepherd 2003 Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice Neoplasia 5 32 40 12659668 10.1016/S1476-5586(03)80015-5 1:CAS:528:DC%2BD3sXhs12ltLo%3D 1502120 Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D’Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S (2003) Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 5:32–40
11. 11. Y Koga VR Naraparaju N Yamamoto 1999 Antitumor effects of vitamin D 3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice Proc Soc Exp Biol Med 220 20 26 9893164 10.3181/00379727-220-44339 1:CAS:528:DyaK1MXjslamsQ%3D%3D Koga Y, Naraparaju VR, Yamamoto N (1999) Antitumor effects of vitamin D 3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Proc Soc Exp Biol Med 220:20–26
12. 12. H Koprowski M Herlyn Z Steplewski HF Sears 1981 Specific antigen in serum of patients with colon carcinoma Science 212 53 55 6163212 10.1126/science.6163212 1:STN:280:DyaL3M7ltlWjtg%3D%3D Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981) Specific antigen in serum of patients with colon carcinoma. Science 212:53–55
13. 13. RP Link KL Perlman EA Pierce HK Schnoes HF DeLuca 1986 Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D 3-Sepharose chromatography Anal Biochem 157 262 269 3777429 10.1016/0003-2697(86)90624-X 1:CAS:528:DyaL28Xmt1WqtbY%3D Link RP, Perlman KL, Pierce EA, Schnoes HK, DeLuca HF (1986) Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D 3-Sepharose chromatography. Anal Biochem 157:262–269
14. 14. Y Maehara S Kohnoe K Sugimachi 1990 Chemosensitivity test for carcinoma of digestive organs Semin Surg Oncol 6 42 47 2154026 10.1002/ssu.2980060109 1:STN:280:DyaK3c7ktVSltA%3D%3D Maehara Y, Kohnoe S, Sugimachi K (1990) Chemosensitivity test for carcinoma of digestive organs. Semin Surg Oncol 6:42–47
15. 15. D Morton FR Eibler RA Malmgren WC Wood 1970 Immunological factors which influence response to immunotherapy in malignant melanoma Surgery 68 158 164 10483463 1:STN:280:DyaK1Mvht12lsw%3D%3D Morton D, Eibler FR, Malmgren RA, Wood WC (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158-164
16. 16. VR Naraparaju N Yamamoto 1994 Roles of ß-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages Immunol Lett 43 143 148 7721326 10.1016/0165-2478(94)90214-3 1:CAS:528:DyaK2MXjt1Sltr0%3D Naraparaju VR, Yamamoto N (1994) Roles of ß-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol Lett 43:143–148
17. 17. BZ Ngwenya N Yamamoto 1985 Activation of peritoneal macrophages by lysophosphatidylcholine Biochim Biophys Acta 839 9 15 3978122 10.1016/0304-4165(85)90175-8 1:CAS:528:DyaL2MXksFalsrs%3D Ngwenya BZ, Yamamoto N (1985) Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys Acta 839:9-15
18. 18. BZ Ngwenya N Yamamoto 1986 Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages Cancer Immunol Immunother 21 174 182 2938735 10.1007/BF00199358 1:CAS:528:DyaL28XktVCqtrk%3D Ngwenya BZ, Yamamoto N (1986) Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol Immunother 21:174–182
19. 19. BZ Ngwenya N Yamamoto 1990 Contribution of lysophosphatidylcholine treated nonadherent cells to mechanism of macrophage activation Proc Soc Exp Biol Med 193 118 124 2300592 10.3181/00379727-193-43011 1:CAS:528:DyaK3cXhslKrt7o%3D Ngwenya BZ, Yamamoto N (1990) Contribution of lysophosphatidylcholine treated nonadherent cells to mechanism of macrophage activation. Proc Soc Exp Biol Med 193:118–124
20. 20. RM Olson NP Perencevich AW Malcolm JT Chaffey RE Wilson 1980 Pattern of recurrence following curative resection of adenocarinoma of the colon and rectum Cancer 45 2969 2974 7388740 10.1002/1097-0142(19800615)45:12<2969::AID-CNCR2820451214>3.0.CO;2-7 1:STN:280:DyaL3c3it1CnsQ%3D%3D Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE (1980) Pattern of recurrence following curative resection of adenocarinoma of the colon and rectum. Cancer 45:2969–2974
21. 21. T Rich LL Gunderson R Lew JJ Galdibini AM Cohen G Donaldson 1983 Patterns of recurrence of rectal cancer after potentially curative surgery Cancer 52 1317 1329 6192900 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6 1:STN:280:DyaL3s3osVOruw%3D%3D Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G (1983) Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 52:1317–1329
22. 22. N Yamamoto BZ Ngwenya 1987 Activation of macrophages by lysophospholipids, and ether derivatives of neutral lipids and phospholipids Cancer Res 47 2008 2013 2950993 1:CAS:528:DyaL2sXktVGmt78%3D Yamamoto N, Ngwenya BZ (1987) Activation of macrophages by lysophospholipids, and ether derivatives of neutral lipids and phospholipids. Cancer Res 47:2008-2013
23. 23. N Yamamoto BZ Ngwenya PA Pieringer 1987 Activation of macrophages by ether analogues of lysophospholipids Cancer Immunol Immunother 25 185 192 2824051 10.1007/BF00199146 1:CAS:528:DyaL1cXhtVKisr4%3D Yamamoto N, Ngwenya BZ, Pieringer PA (1987) Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunol Immunother 25:185–192
24. 24. N Yamamoto DA St. Claire S Homma BZ Ngwenya 1988 Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues Cancer Res 48 6044 6049 3167855 1:CAS:528:DyaL1cXmt1ynsrs%3D Yamamoto N, St. Claire DA, Homma S, Ngwenya BZ (1988) Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res 48:6044–6049
25. 25. N Yamamoto S Homma 1991 Vitamin D 3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal from lysophosphatidylcholine-treated lymphocytes Proc Natl Acad Sci USA 88 8539 8543 1924312 10.1073/pnas.88.19.8539 1:CAS:528:DyaK3MXmsFCisrg%3D 52544 Yamamoto N, Homma S (1991) Vitamin D 3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88:8539–8543
26. 26. N Yamamoto S Homma JG Haddad MN Kowalski 1991 Vitamin D 3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells Immunol 74 420 424 1:CAS:528:DyaK38Xlslartg%3D%3D Yamamoto N, Homma S, Haddad JG, Kowalski MN (1991) Vitamin D 3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunol 74:420–424
27. 27. N Yamamoto S Homma I Millman 1991 Identification of the serum factor required for in vitro activation of macrophages: role of vitamin D binding protein (group-specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages J Immunol 147 273 280 2051023 1:CAS:528:DyaK3MXlsFKrtbg%3D Yamamoto N, Homma S, Millman I (1991) Identification of the serum factor required for in vitro activation of macrophages: role of vitamin D binding protein (group-specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 147:273–280
28. 28. Yamamoto N (1993) In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor. US Patent number: 5,177,002
29. 29. N Yamamoto R Kumashiro 1993 Conversion of vitamin D 3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of ß-galactosidase of B cells and sialidase of T cells J Immunol 151 2794 2902 8360493 1:CAS:528:DyaK3sXmsVOqsbg%3D Yamamoto N, Kumashiro R (1993) Conversion of vitamin D 3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of ß-galactosidase of B cells and sialidase of T cells. J Immunol 151:2794–2902
30. 30. N Yamamoto R Kumashiro M Yamamoto NP Willett DD Lindsay 1993 Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D 3-binding protein and albumin Infect Immun 61 5388 5891 8225612 1:CAS:528:DyaK2cXlt1KhsA%3D%3D 281327 Yamamoto N, Kumashiro R, Yamamoto M, Willett NP, Lindsay DD (1993) Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D 3-binding protein and albumin. Infect Immun 61:5388–5891
31. 31. Yamamoto N (1994) Macrophage activating factor from vitamin D binding protein. US Patent Number: 5,326,749
32. 32. N Yamamoto VR Naraparaju SM Srinivasula 1995 Structural modification of serum vitamin D 3-binding protein and immunosuppression in HIV-infected patients AIDS Res Human Retrovirus 11 1373 1378 10.1089/aid.1995.11.1373 1:STN:280:DyaK287lvFWgtw%3D%3D Yamamoto N, Naraparaju VR, Srinivasula SM (1995) Structural modification of serum vitamin D 3-binding protein and immunosuppression in HIV-infected patients. AIDS Res Human Retrovirus 11:1373–1378
33. 33. N Yamamoto 1996 Structural definition of a potent macrophage activating factor derived from vitamin D 3 binding protein with adjuvant activity for antibody production Mol Immunol 33 1157 1164 9070663 10.1016/S0161-5890(96)00081-8 1:CAS:528:DyaK2sXitVyhtL4%3D Yamamoto N (1996) Structural definition of a potent macrophage activating factor derived from vitamin D 3 binding protein with adjuvant activity for antibody production. Mol Immunol 33:1157–1164
34. 34. N Yamamoto VR Naraparaju SO Asbell 1996 Deglycosylation of serum vitamin D-binding protein and immunosuppression in cancer patients Cancer Res 56 2827 2831 8665521 1:STN:280:DyaK283nsFOmtA%3D%3D Yamamoto N, Naraparaju VR, Asbell SO (1996) Deglycosylation of serum vitamin D-binding protein and immunosuppression in cancer patients. Cancer Res 56:2827–2831
35. 35. Yamamoto N (1997) Diagnostic and prognostic indices for cancer and AIDS. US Patent Number: 5,620,846
36. 36. N Yamamoto VR Naraparaju 1997 Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor Cancer Res 57 2187 2191 9187119 1:CAS:528:DyaK2sXjslGksLc%3D Yamamoto N, Naraparaju VR (1997) Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 57:2187–2191
37. 37. N Yamamoto VR Naraparaju M Urade 1997 Prognostic utility of serum a-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients Cancer Res 57 295 299 9000571 1:CAS:528:DyaK2sXntFKhtg%3D%3D Yamamoto N, Naraparaju VR, Urade M (1997) Prognostic utility of serum a-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 57:295–299
38. 38. N Yamamoto 1998 Vitamin D and the immune system PJ Delves I Roitt Encyclopedia of immunology 2 Academic London 2494 2499 10.1006/rwei.1999.0630 Yamamoto N (1998) Vitamin D and the immune system. In: Delves PJ, Roitt I (eds) Encyclopedia of immunology, 2nd edn. Academic, London, pp 2494–2499
39. 39. Yamamoto N (1998) Diagnostic and prognostic ELISA assays of serum or plasma a-N-acetylgalactosaminidase for cancer. US Patent number: 5,712,104
40. 40. N Yamamoto VR Naraparaju 1998 Structurally well-defined macrophage activating factor derived from vitamin D 3-binding protein has a potent adjuvant activity for immunization Immunol Cell Biol 76 237 244 9682967 10.1046/j.1440-1711.1998.00748.x 1:CAS:528:DyaK1cXltFCluro%3D Yamamoto N, Naraparaju VR (1998) Structurally well-defined macrophage activating factor derived from vitamin D 3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol 76:237–244
41. 41. Yamamoto N (2002) Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis. US Patent no. 6,410,269
42. 42. N Yamamoto M Ueda 2004 Eradication of HIV by treatment of HIV-infected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Immunology 2000 Medmond Ltd Bolonia 197 200 Yamamoto N, Ueda M (2004) Eradication of HIV by treatment of HIV-infected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Immunology 2000. Medmond Ltd, Bolonia, pp 197–200
43. 43. N Yamamoto M Ueda 2004 Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology 2000 Medmond Ltd Bolonia 201 204 Yamamoto N, Ueda M (2004) Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology 2000. Medmond Ltd, Bolonia, pp 201–204
44. 44. N Yamamoto M Urade 2005 Pathogenic significance of a-N-acetylgalactosaminidase found in the hemagglutinin of influenza virus Microbes Infect 7 674 681 15848273 10.1016/j.micinf.2005.01.015 1:CAS:528:DC%2BD2MXkt1Gnsbw%3D Yamamoto N, Urade M (2005) Pathogenic significance of a-N-acetylgalactosaminidase found in the hemagglutinin of influenza virus. Microbes Infect 7:674–681
45. 45. N Yamamoto 2006 Pathogenic significance of a-N-acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1 AIDS Res Human Retrovirus 22 262 271 10.1089/aid.2006.22.262 1:CAS:528:DC%2BD28XisFyht7o%3D Yamamoto N (2006) Pathogenic significance of a-N-acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res Human Retrovirus 22:262–271
46. 46. N Yamamoto H Suyama N-Y Yamamoto N Ushijima 2008 Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) Int J Cancer 122 461 467 17935130 10.1002/ijc.23107 1:CAS:528:DC%2BD2sXhsVOnsrnN Yamamoto N, Suyama H, Yamamoto N-Y, Ushijima N (2008) Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 122:461–467
47. 47. B Zbar T Tanaka 1971 Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis Science 172 271 273 4323415 10.1126/science.172.3980.271 1:STN:280:DyaE3M7jvV2htw%3D%3D Zbar B, Tanaka T (1971) Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172:271-273
48. 48. S Zhang HS Zhang C Cordon-Cardo G Ragupathi PO Livingston 1998 Selection of tumor antigens as targets for immune attack using immunohistochemistry. III. Protein antigen Clin Cancer Res 4 2669 2676 9829729 1:CAS:528:DyaK1cXns1Ogtbs%3D Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry. III. Protein antigen. Clin Cancer Res 4:2669–2676